Artelo Biosciences (ARTL)
(Delayed Data from NSDQ)
$1.20 USD
-0.02 (-1.64%)
Updated Sep 17, 2024 03:07 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ARTL 1.20 -0.02(-1.64%)
Will ARTL be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARTL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARTL
Artelo's (ARTL) FABP5 Inhibitor Effective in Pre-Clinical Study
ARTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARTL
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
UK dividends calendar
UK dividends calendar
UK dividends calendar
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference